2026 Q2 - tulosraportti
62 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 312 | ||
| 153 | ||
| 783 | ||
| 167 | ||
| 2 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sittenI am almost starting to get more excited about the collaboration partners we *don't* know who are, than the ones we actually know. Acuitas, Tcelltech, Full Circles, 4basebio and the others we have heard about until we dream about lipid nanoparticles at night. But over 10 R&D collaborations in the screening program... and some of them even refuse to let their name be mentioned out loud. What on earth is going on behind the scenes? Imagine if the ultimate DNA technology comes from a company operating out of a basement in Singapore? Or that the perfect T-cell LNP is being developed by three researchers and a labrador in Basel? Maybe the winner is already sitting right among the known ones. Maybe it is still walking around with a cardboard mask and snorkel. And we are sitting here like a bunch of sleepless detectives analyzing every single post, every patent and every LinkedIn like as if it were going to decide the end of the world. Welcome to season 2 of: THE MASKED LNP Who is hiding behind the nanoparticle this time? Is it a stealth biotech? A pharma giant in disguise? Or just someone who doesn't want us to bother them? Theories are received in the room. No theory is too wild. (We have lost our night's sleep anyway.)
It looks like someone wants to withhold information to avoid a share price explosion. Wonder how many are "sniffing" around Circio, and when we will see the first "move"?
·2 päivää sitten · MuokattuTraders week. A lot is happening now in Circio. Many collaborations, many results and strategies to be evaluated. Remember that there have been a flurry of failed studies in gene and cell therapy studies. Initiated too early a couple three years ago. Novartis, Lilly etc are cutting studies in phase 2, Lilly most recently yesterday in Alzheimer's. The arguably worst is last year's Astra Zeneca acquisition of EsoBiotec for 1 billion USD which failed with fatalities less than 6 months after payment in phase 1 - Lentivirus-based. It makes you wonder what competence is floating around in the corridors of certain big pharma. Generation 1 technologies in phase 1 and 2 are now phasing out. It is therefore important that Circio takes its time and makes the right choices now as generation 2 develops. They see that a lot of new things are coming - AAV Capsides, LNP in various variants, peptide technology and others, but the actual engine that creates durability and high efficacy, that is mainly circVec which stands out. Those who have bought Orna and Orbital et al are probably trying as long as possible to cling to synthetic due to large investments, but there is only one DNA based - circVec - that outperforms everything currently according to what is known. A better starting point for creating FOMO among big pharma is hard to have. You cannot trade towards a sudden piece of news. You can only hedge against it by holding. Through thick and thin. Circio has top international competence, possibly better than what is in certain big pharma. Have a good weekend.
- Poistettu·2 päivää sittenWhere are you bennyz?! You Norwegian forest troll! 😂
·2 päivää sittenLooking at today's chart for CRNA, it is impossible not to notice the sharp, rapid fluctuations. Such sudden jumps and drops are largely due to algorithms and trading bots running loops based on short-term indicators like STO and MACD. When the price is tested towards the 10 level, they trigger automatic triggers.
·2 päivää sittenVerily I say unto you, it is tough to be long-term at times......
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
62 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenI am almost starting to get more excited about the collaboration partners we *don't* know who are, than the ones we actually know. Acuitas, Tcelltech, Full Circles, 4basebio and the others we have heard about until we dream about lipid nanoparticles at night. But over 10 R&D collaborations in the screening program... and some of them even refuse to let their name be mentioned out loud. What on earth is going on behind the scenes? Imagine if the ultimate DNA technology comes from a company operating out of a basement in Singapore? Or that the perfect T-cell LNP is being developed by three researchers and a labrador in Basel? Maybe the winner is already sitting right among the known ones. Maybe it is still walking around with a cardboard mask and snorkel. And we are sitting here like a bunch of sleepless detectives analyzing every single post, every patent and every LinkedIn like as if it were going to decide the end of the world. Welcome to season 2 of: THE MASKED LNP Who is hiding behind the nanoparticle this time? Is it a stealth biotech? A pharma giant in disguise? Or just someone who doesn't want us to bother them? Theories are received in the room. No theory is too wild. (We have lost our night's sleep anyway.)It looks like someone wants to withhold information to avoid a share price explosion. Wonder how many are "sniffing" around Circio, and when we will see the first "move"?
- ·2 päivää sitten · MuokattuTraders week. A lot is happening now in Circio. Many collaborations, many results and strategies to be evaluated. Remember that there have been a flurry of failed studies in gene and cell therapy studies. Initiated too early a couple three years ago. Novartis, Lilly etc are cutting studies in phase 2, Lilly most recently yesterday in Alzheimer's. The arguably worst is last year's Astra Zeneca acquisition of EsoBiotec for 1 billion USD which failed with fatalities less than 6 months after payment in phase 1 - Lentivirus-based. It makes you wonder what competence is floating around in the corridors of certain big pharma. Generation 1 technologies in phase 1 and 2 are now phasing out. It is therefore important that Circio takes its time and makes the right choices now as generation 2 develops. They see that a lot of new things are coming - AAV Capsides, LNP in various variants, peptide technology and others, but the actual engine that creates durability and high efficacy, that is mainly circVec which stands out. Those who have bought Orna and Orbital et al are probably trying as long as possible to cling to synthetic due to large investments, but there is only one DNA based - circVec - that outperforms everything currently according to what is known. A better starting point for creating FOMO among big pharma is hard to have. You cannot trade towards a sudden piece of news. You can only hedge against it by holding. Through thick and thin. Circio has top international competence, possibly better than what is in certain big pharma. Have a good weekend.
- Poistettu·2 päivää sittenWhere are you bennyz?! You Norwegian forest troll! 😂
- ·2 päivää sittenLooking at today's chart for CRNA, it is impossible not to notice the sharp, rapid fluctuations. Such sudden jumps and drops are largely due to algorithms and trading bots running loops based on short-term indicators like STO and MACD. When the price is tested towards the 10 level, they trigger automatic triggers.
- ·2 päivää sittenVerily I say unto you, it is tough to be long-term at times......
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 312 | ||
| 153 | ||
| 783 | ||
| 167 | ||
| 2 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
62 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenI am almost starting to get more excited about the collaboration partners we *don't* know who are, than the ones we actually know. Acuitas, Tcelltech, Full Circles, 4basebio and the others we have heard about until we dream about lipid nanoparticles at night. But over 10 R&D collaborations in the screening program... and some of them even refuse to let their name be mentioned out loud. What on earth is going on behind the scenes? Imagine if the ultimate DNA technology comes from a company operating out of a basement in Singapore? Or that the perfect T-cell LNP is being developed by three researchers and a labrador in Basel? Maybe the winner is already sitting right among the known ones. Maybe it is still walking around with a cardboard mask and snorkel. And we are sitting here like a bunch of sleepless detectives analyzing every single post, every patent and every LinkedIn like as if it were going to decide the end of the world. Welcome to season 2 of: THE MASKED LNP Who is hiding behind the nanoparticle this time? Is it a stealth biotech? A pharma giant in disguise? Or just someone who doesn't want us to bother them? Theories are received in the room. No theory is too wild. (We have lost our night's sleep anyway.)It looks like someone wants to withhold information to avoid a share price explosion. Wonder how many are "sniffing" around Circio, and when we will see the first "move"?
- ·2 päivää sitten · MuokattuTraders week. A lot is happening now in Circio. Many collaborations, many results and strategies to be evaluated. Remember that there have been a flurry of failed studies in gene and cell therapy studies. Initiated too early a couple three years ago. Novartis, Lilly etc are cutting studies in phase 2, Lilly most recently yesterday in Alzheimer's. The arguably worst is last year's Astra Zeneca acquisition of EsoBiotec for 1 billion USD which failed with fatalities less than 6 months after payment in phase 1 - Lentivirus-based. It makes you wonder what competence is floating around in the corridors of certain big pharma. Generation 1 technologies in phase 1 and 2 are now phasing out. It is therefore important that Circio takes its time and makes the right choices now as generation 2 develops. They see that a lot of new things are coming - AAV Capsides, LNP in various variants, peptide technology and others, but the actual engine that creates durability and high efficacy, that is mainly circVec which stands out. Those who have bought Orna and Orbital et al are probably trying as long as possible to cling to synthetic due to large investments, but there is only one DNA based - circVec - that outperforms everything currently according to what is known. A better starting point for creating FOMO among big pharma is hard to have. You cannot trade towards a sudden piece of news. You can only hedge against it by holding. Through thick and thin. Circio has top international competence, possibly better than what is in certain big pharma. Have a good weekend.
- Poistettu·2 päivää sittenWhere are you bennyz?! You Norwegian forest troll! 😂
- ·2 päivää sittenLooking at today's chart for CRNA, it is impossible not to notice the sharp, rapid fluctuations. Such sudden jumps and drops are largely due to algorithms and trading bots running loops based on short-term indicators like STO and MACD. When the price is tested towards the 10 level, they trigger automatic triggers.
- ·2 päivää sittenVerily I say unto you, it is tough to be long-term at times......
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 312 | ||
| 153 | ||
| 783 | ||
| 167 | ||
| 2 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt